Literature DB >> 2014283

Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis.

M J Lee1, P F Hahn, N Papanicolaou, T K Egglin, S Saini, P R Mueller, J F Simeone.   

Abstract

In a retrospective study of adrenal masses evaluated with computed tomography (CT), lesion x-ray attenuation was compared with size and radiologists' interpretations in discriminating benign lesions from malignant ones. Unenhanced CT attenuation coefficient and size were analyzed electronically in 55 patients with 66 adrenal masses. There were 38 nonhyperfunctioning adenomas in 33 patients and 28 malignant masses in 22 patients. Primary extraadrenal malignancies were present in 45 of the 55 patients. Three blinded readers characterized the adrenal masses using a seven-point scale of certainty. Results were subjected to receiver operating characteristic (ROC) analysis. The mean CT attenuation coefficient for benign adrenal masses was -2.2 HU +/- 16.0 and was significantly different from the mean for malignant lesions (28.9 HU +/- 10.6). The area under the ROC curve for CT attenuation coefficients (0.91 +/- 0.04) was significantly larger than that for lesion size (0.84 +/- 0.05) or best observer interpretation (0.84 +/- 0.05). A threshold CT attenuation value of 0 HU had a sensitivity-to-specificity ratio of 47%:100% for characterizing benign adrenal masses, whereas a threshold attenuation of 10 HU had a ratio of 79%:96%.

Entities:  

Mesh:

Year:  1991        PMID: 2014283     DOI: 10.1148/radiology.179.2.2014283

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  48 in total

Review 1.  Minimal access adrenal surgery.

Authors:  L M Brunt
Journal:  Surg Endosc       Date:  2006-01-25       Impact factor: 4.584

2.  Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors?

Authors:  C Pohlink; A Tannapfe; U Eichfeld; F Schmidt; D Führer; R Paschke; C A Koch
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 3.  The clinical evaluation of silent adrenal masses.

Authors:  B Ambrosi; E Passini; T Re; L Barbetta
Journal:  J Endocrinol Invest       Date:  1997-02       Impact factor: 4.256

4.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

Review 5.  Management of Adrenal Masses.

Authors:  Hattangadi Sanjay Bhat; Balagopal Nair Tiyadath
Journal:  Indian J Surg Oncol       Date:  2016-12-17

6.  Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?

Authors:  L Tessonnier; F Sebag; F F Palazzo; C Colavolpe; C De Micco; J Mancini; B Conte-Devolx; J F Henry; O Mundler; D Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

Review 7.  Adrenal sparing surgery in the treatment of renal cell carcinoma: when is it possible?

Authors:  R Autorino; G Di Lorenzo; R Damiano; S Perdonà; A Oliva; M D'Armiento; M De Sio
Journal:  World J Urol       Date:  2003-07-12       Impact factor: 4.226

8.  Differentiation of adrenal adenoma and nonadenoma in unenhanced CT: new optimal threshold value and the usefulness of size criteria for differentiation.

Authors:  Sung Hee Park; Myeong-Jin Kim; Joo Hee Kim; Joon Seok Lim; Ki Whang Kim
Journal:  Korean J Radiol       Date:  2007 Jul-Aug       Impact factor: 3.500

Review 9.  The indeterminate adrenal lesion.

Authors:  Anju Sahdev; Jon Willatt; Isaac R Francis; Rodney H Reznek
Journal:  Cancer Imaging       Date:  2010-03-18       Impact factor: 3.909

Review 10.  The indeterminate adrenal mass in patients with cancer.

Authors:  A Sahdev; R H Reznek
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.